Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

Open access
Gayle, Sophia, Landrette, Sean, Beeharry, Neil, Conrad, Chris, Hernandez, Marylens, Beckett, Paul, Ferguson, Shawn M., Mandelkern, Talya, Zheng, Meiling, Xu, Tian, Rothberg, Jonathan, Lichenstein, Henri·2017·Blood

Abstract

Key Points: Apilimod has broad anticancer activity in vitro and in vivo across all subtypes of B-NHL. Apilimod induces B-NHL cytotoxicity through a unique mechanism of action that involves the disruption of lysosomal function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2016-09-736892

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 202

Metadata

Authors
Gayle, S., Landrette, S., Beeharry, N., Conrad, C., Hernandez, M., Beckett, P., Ferguson, S. M., Mandelkern, T., Zheng, M., Xu, T., Rothberg, J., & Lichenstein, H.
Venue
Blood
Published
2017-03-30
Volume
129
Issue
13
Pages
1768-1778
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2571667968
Cited by
202
References
10
FWCI
11.31
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2016-09-736892
The paper
Gayle, S., Landrette, S., Beeharry, N., Conrad, C., Hernandez, M., Beckett, P., Ferguson, S. M., Mandelkern, T., Zheng, M., Xu, T., Rothberg, J., & Lichenstein, H. (2017). Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2016-09-736892

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.